Health News Archive - February 24, 2009
ROCKVILLE, Md. and EMERYVILLE, Calif., Feb. 24 /PRNewswire/ -- Innovative Biosensors, Inc., and ProGenTech Limited, two emerging leaders in life science & diagnostics, today announced an agreement to jointly develop a rapid, integrated diagnostic system.
AMSTERDAM, the Netherlands, February 24 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year of 2008. Highlights - Extra clinical trial in LPL deficiency causes a delay of the announced filing date for lead product GlyberaTM which is now expected H2 2009 - Positive clinical data on GlyberaTM - CEO Ronald Lorijn resigned for personal reasons - Start of clinical multicenter Hemophilia B trial in 2009 - Start development of treatments for Duchenne Muscular Dystrophy and Parkinson's disease - Scale up of unique and proprietary production platform to fully support worldwide commercial supply for current products - Independent supervisory board with three new members bringing extensive knowledge and experience. - Key financial figures in line with guidance - Cash & cash equivalents of EUR 34.2 million at December 31,
Performing a mentally fatiguing task prior to an exercise test can result in people feeling more exhausted, Welsh researchers said. The study also found that mental fatigue did not cause the heart or muscles to perform any differently -- instead, people's perceived effort determines when people reach exhaustion. Samuele M.
Teens who prefer popular songs with degrading sexual references are more likely to engage in intercourse or in pre-coital activities, U.S. researchers say. Dr. Brian A.
LONDON, February 24 /PRNewswire/ -- - Syndicate Comprises Leading Sector Investors Clarus Ventures, MVM Life Science Partners and Novartis Option Fund Heptares Therapeutics Ltd, the drug discovery company focused on drugs targeting G-protein-coupled receptors (GPCRs), announces today it has raised GBP21 million (US$30 million) of equity finance in a successful Series A private round from three blue-chip international venture capital firms. Clarus Ventures led the syndicate, which includes the founding investor, MVM Life Science Partners, and the Novartis Option Fund.
National Campaign Aims to Protect Healthcare Workers from Hazardous Drug Exposure COLUMBUS, Ohio, Feb.
Like general anesthesia without the risks CORONA DEL MAR, Calif., Feb. 24 /PRNewswire/ -- General anesthesia (GA) remains a popular anesthetic for cosmetic surgery. More enlightened surgeons and anesthesia providers avoid GA for cosmetic surgery.
Respected Researcher Provides Extensive Experience In Molecular Diagnostics SALT LAKE CITY, Feb. 24 /PRNewswire/ -- Axial Biotech, Inc., a company revolutionizing spine care through the development of molecular diagnostic technologies, announced today that Roberto A.
New Clinical Advisory Board Established to Provide Industry Leadership and Ophthalmology Experience ZURICH, Switzerland, Feb.
BOSTON, Feb. 24 /PRNewswire-FirstCall/ -- Perceptive Informatics, the industry's leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced that it has received the Frost & Sullivan Product Line Strategy Award.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.